Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014
Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Regulation of inflammatory cytokines in human immunocompetent cells by propranolol in vitro Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology Year: 2016
Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013
Differential effects of simvastatin and dexamethasone on TLR3-induced anti-viral cytokines in asthmatic epithelium Source: Annual Congress 2013 –Studies of asthma in man Year: 2013
Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Decoy chemokine neutraligands with anti-asthmatic activity Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
In vitro profile of the new inhaled pan-JAK inhibitor LAS194046Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
In vivo efficacy of CHF6001, an inhaled PDE4 inhibitor with a wide therapeutic window Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014
Inhibition of matrix metalloproteinase-2 activity by propranolol in immunocompetent cells Source: Annual Congress 2013 –Studies of asthma in man Year: 2013
In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013
Osteopontin binds and modulate the antibacterial action of eosinophil-recruiting chemokines during allergic inflammation Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015
CHI-91040, a novel inhaled p38α inhibitor, counteracts lung inflammation induced by IL-1β in the rat Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
The anti-inflammatory effects of eucalyptol in a mouse model of LPS-induced pulmonary inflammation are mediated by TRPM8 Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016